BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 12728439)

  • 1. The role of high-dose rate brachytherapy in locally advanced prostate cancer.
    Vicini FA; Vargas C; Edmundson G; Kestin L; Martinez A
    Semin Radiat Oncol; 2003 Apr; 13(2):98-108. PubMed ID: 12728439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High dose rate brachytherapy in the treatment of prostate cancer.
    Vicini F; Vargas C; Gustafson G; Edmundson G; Martinez A
    World J Urol; 2003 Sep; 21(4):220-8. PubMed ID: 12905008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the outcome and morbidity for localized or locally advanced prostate cancer treated by high-dose-rate brachytherapy plus external beam radiotherapy (EBRT) versus EBRT alone.
    Fang FM; Wang YM; Wang CJ; Huang HY; Chiang PH
    Jpn J Clin Oncol; 2008 Jul; 38(7):474-9. PubMed ID: 18621848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenge of dose escalation in locally advanced unfavourable prostate cancer using HDR brachytherapy.
    Al-Salihi O; Mitra A; Payne H
    Prostate Cancer Prostatic Dis; 2006; 9(4):370-3. PubMed ID: 16832383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer.
    Galalae RM; Martinez A; Mate T; Mitchell C; Edmundson G; Nuernberg N; Eulau S; Gustafson G; Gribble M; Kovács G
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1048-55. PubMed ID: 15001244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypofractionated conformal HDR brachytherapy in hormone naïve men with localized prostate cancer. Is escalation to very high biologically equivalent dose beneficial in all prognostic risk groups?
    Galalae RM; Martinez A; Nuernberg N; Edmundson G; Gustafson G; Gonzalez J; Kimming B
    Strahlenther Onkol; 2006 Mar; 182(3):135-41. PubMed ID: 16520907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3D conformal HDR brachytherapy and external beam irradiation combined with temporary androgen deprivation in the treatment of localized prostate cancer.
    Martin T; Röddiger S; Kurek R; Dannenberg T; Eckart O; Kolotas C; Heyd R; Rogge B; Baltas D; Tunn U; Zamboglou N
    Radiother Oncol; 2004 Apr; 71(1):35-41. PubMed ID: 15066294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Technological advances in radiotherapy for the treatment of localised prostate cancer.
    Mangar SA; Huddart RA; Parker CC; Dearnaley DP; Khoo VS; Horwich A
    Eur J Cancer; 2005 Apr; 41(6):908-21. PubMed ID: 15808957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcome of high dose rate brachytherapy in radiotherapy of localised prostate cancer.
    Aström L; Pedersen D; Mercke C; Holmäng S; Johansson KA
    Radiother Oncol; 2005 Feb; 74(2):157-61. PubMed ID: 15734203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. External beam radiotherapy plus high-dose-rate brachytherapy for treatment of locally advanced prostate cancer: the initial experience of the Catalan Institute of Oncology.
    Pistis F; Guedea F; Pera J; Gutierrez C; Ventura M; Polo A; Martinez E; Boladeras A; Ferrer F; Gabriele P; Linares L
    Brachytherapy; 2010; 9(1):15-22. PubMed ID: 19734106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experiences with a new high-dose-rate brachytherapy (HDR-BT) boost technique for T3b prostate cancer.
    Rades D; Schwarz R; Todorovic M; Thurmann H; Graefen M; Walz J; Schild SE; Dunst J; Alberti W
    Strahlenther Onkol; 2007 Jul; 183(7):398-402. PubMed ID: 17609874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer.
    Hiratsuka J; Jo Y; Yoshida K; Nagase N; Fujisawa M; Imajo Y
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):684-90. PubMed ID: 15183471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypofractionated boost with high-dose-rate brachytherapy and open magnetic resonance imaging-guided implants for locally aggressive prostate cancer: a sequential dose-escalation pilot study.
    Ares C; Popowski Y; Pampallona S; Nouet P; Dipasquale G; Bieri S; Ozsoy O; Rouzaud M; Khan H; Miralbell R
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):656-63. PubMed ID: 19250768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [High-dose-rate brachytherapy with external beam radiotherapy for localized or locally advanced prostate cancer].
    Matsunobu A; Shioyama Y; Uehara S; Ohga S; Atsumi K; Matsumura T; Sakamoto N; Yoshikawa M; Iguchi A; Honda H
    Fukuoka Igaku Zasshi; 2010 Apr; 101(4):75-83. PubMed ID: 20715564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
    Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
    J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High dose rate brachytherapy for prostate cancer.
    Hoskin P
    Cancer Radiother; 2008 Nov; 12(6-7):512-4. PubMed ID: 18755623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LDR vs. HDR brachytherapy for localized prostate cancer: the view from radiobiological models.
    King CR
    Brachytherapy; 2002; 1(4):219-26. PubMed ID: 15062170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.